Atherotech to add new apoA1 measurement and apoB:apoA1 ratio to its comprehensive cholesterol test, further identifying patients at risk of
BIRMINGHAM, Ala., Nov. 6 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced it will be exhibiting its VAP(R) Cholesterol Test in booth No. 2918 at the American Heart Association Scientific Sessions 2008. The annual meeting takes place Nov. 8-12 at the Ernest N. Morial Convention Center in New Orleans.
Atherotech representatives will be available to discuss the VAP Cholesterol Test during regular exhibit hours on October 9, 10 and 11 in booth No. 2918, and the VAP Test will be provided via blood draw to qualified attendees. Test results will be returned via mail after the conference.
The VAP (vertical auto profile) Test is the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters - LDL, non-HDL and apoB - considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology.
"Detailed risk profiling through advanced lipid testing is changing the way we evaluate and manage heart disease risk," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The VAP Test is affordable, widely covered by insurance and will play an increasingly important role in heart attack and stroke prevention."
The VAP Test reports all 15 lipoprotein measurements with a single
test, and unlike other lipid profiles, it directly measures LDL and HDL and
includes Lp(a) and apoB as part of its standard test. Atherotech has
announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early
2009. ApoA1 is the main component of protective HDL cholesterol and studies
have shown that the apoB:apoA1 ratio may correlate better with increased
risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL
|SOURCE Atherotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved